Table 1 Patients’ and disease characteristics
Age | |
 median (range), years | 61 (41–88) |
  ≤ 60, N (%) | 86 (46) |
  > 60 to ≤70, N (%) | 64 (34) |
  > 70 to ≤80, N (%) | 27 (15) |
  > 80, N (%) | 9 (5) |
Gender, N (%) | |
 female | 40 (22) |
 male | 146 (79) |
Smoking status | |
 never smoker | 17 (6) |
 previous smoker | 33 (31) |
 current smoker | 58 (54) |
 missing | 108 |
High risk alcohol consumption | |
 No | 49 (46) |
 Yes | 54 (51) |
 in the past | 4 (4) |
 missing | 79 |
Karnofsky Performance Status | |
 median (range) | 90 (50–100) |
  > 70, N (%) | 160 (86) |
  ≤ 70, N (%) | 26 (14) |
Oncological resection of primary tumor | |
 yes | 56 (30) |
 no | 130 (70) |
Induction chemotherapy | |
 yes | 15 (8) |
 no | 171 (92 |
Concomitant systemic therapy | |
 no | 38 (20) |
 cisplatin or carboplatin | 125 (67) |
 cetuximab | 23 (12) |
Site of primary tumor, N (%) | |
 oral cavity | 52 (28) |
 oropharynx | 83 (45) |
 hypopharynx | 27 (15) |
 larynx | 24 (13) |
UICC stage, N (%) | |
 I | 5 (3) |
 II | 11 (6) |
 III | 44 (24) |
 IV | 126 (68) |
Tumor grade, N (%) | |
 G1 | 1 (1) |
 G2 | 113 (61) |
 G3 | 72 (39) |
Hemoglobin (g/dL) | |
 median (IQR) | 13.3 (12.0–14.4) |
 missing | 12 |
Neutrophil-to-lymphocyte ratio | |
 median (IQR) | 3.28 (2.15–4.70) |
 missing | 20 |
Platelet-to-lymphocyte ratio | |
 median (IQR) | 189 (136–254) |
 missing | 20 |